Damora Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Damora Therapeutics, Inc. carries a market capitalization of 1.20B, placing it among publicly traded companies globally. Its enterprise value stands at 1.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.20B |
| Enterprise Value | 1.20B |
Share Statistics
Damora Therapeutics, Inc. currently has 61.73M shares outstanding.
| Shares Outstanding | 61.73M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 4.16 |
| P/TBV Ratio | 4.16 |
| P/FCF Ratio | -18.84 |
| P/OCF Ratio | -18.84 |
Financial Position
Damora Therapeutics, Inc. maintains a current ratio of 19.73, meaning it holds 19.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 19.73 |
| Quick Ratio | 19.65 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -132.85 |
| Return on Assets (ROA) | -94.32 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 341,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Damora Therapeutics, Inc.'s stock has gained approximately 105.62036% over the past 52 weeks. The 50-day moving average sits at 25.23, while the 200-day moving average is 25.67.
| Beta (5Y) | N/A |
| 52-Week Price Change | 105.62036% |
| 50-Day Moving Average | 25.23 |
| 200-Day Moving Average | 25.67 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -270.56M, while operating income came in at -270.66M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -270.66M |
| Pretax Income | -262.48M |
| Net Income | -262.83M |
| EBITDA | -270.56M |
| EBIT | -270.66M |
| Earnings Per Share (EPS) | -8.15 |
Balance Sheet
Total book value stands at 386.06M, with working capital of 516.04M providing operational flexibility.
| Cash & Cash Equivalents | 540.52M |
| Total Debt | N/A |
| Net Debt | -540.51M |
| Equity (Book Value) | 386.06M |
| Book Value Per Share | 6.25 |
| Working Capital | 516.04M |
Cash Flow
Damora Therapeutics, Inc. produced -44.51M in operating cash flow over the past twelve months.
| Operating Cash Flow | -44.51M |
| Capital Expenditures | N/A |
| Free Cash Flow | -44.51M |
| FCF Per Share | -1.38 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -20.27 |
| FCF Yield | -5.31 |
Scores
Damora Therapeutics, Inc. posts an Altman Z-Score of 33.03, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 33.03 |